Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 12/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | KCNK13 | Q9HB14 | 2/20 | 0.36 |
| ▸ | PRKACA | P17612 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | MPL | P40238 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30449560 | 1.00 | IDO1 (0.41) | IDO1ARPIK3CAKCNK13PRKACA | |
| SCHEMBL21118140 | 0.88 | NOTUM (0.41) | IDO1ARPRKACARPS6KB1GSK3B | |
| SCHEMBL20653617 | 0.87 | IDO1 (0.44) | IDO1KCNK13PRKACARPS6KB1GSK3B | |
| SCHEMBL16706551 | 0.85 | IDO1 (0.42) | IDO1KCNK13PRKACARPS6KB1GSK3B | |
| SCHEMBL179729 | 0.84 | IDO1 (0.46) | IDO1ARPIK3CA | |
| SCHEMBL30449198 | 0.84 | IDO1 (0.42) | IDO1PIK3CAKCNK13PRKACARPS6KB1 | |
| SCHEMBL122395 | 0.84 | IDO1 (0.42) | IDO1PIK3CAKCNK13PRKACARPS6KB1 | |
| SCHEMBL123581 | 0.84 | IDO1 (0.54) | IDO1KCNK13PRKACARPS6KB1GSK3B | |
| SCHEMBL29376679 | 0.84 | IDO1 (0.54) | IDO1KCNK13PRKACARPS6KB1GSK3B | |
| Iodide SCHEMBL145298 | 0.84 | IDO1 (0.46) | IDO1ARPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139857-B | Sulfoximine, sulfoximinamide, sulfodiimine, and diimine sulfonamide compounds as indoleamine 2,3-dioxygenase inhibitors | 重庆复尚源创医药技术有限公司 | 2023-07-21 | — | — | CN | disclosed |
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| US-11168078-B2 | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11168078-B2 | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| US-20210070742-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | FOCHON BIOSCIENCES, LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| US-20210070742-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | FOCHON BIOSCIENCES, LTD. (CN) | 2021-03-11 | — | — | US | disclosed |
| WO-2018095432-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2, 3-DIOXYGENASE | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | IDO1, IDO2, KYNU | IDO1 1/4885AR 644/4885PIK3CA 1987/4885 |
| US-20210070742-A1 | SULFOXIMINE, SULFONIMIDAMIDE, SULFONDIIMINE AND DIIMIDOSULFONAMIDE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TST | IDO1 1/4885AR 4110/4885PIK3CA 3038/4885 |
| US-11168078-B2 | Sulfoximine, sulfonimidamide, sulfondiimine and diimidosulfonamide compounds as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, TST | IDO1 1/4885AR 4110/4885PIK3CA 3038/4885 |
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | IDO1, IDO2, KYNU | IDO1 1/4885AR 2206/4885PIK3CA 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.